500 related articles for article (PubMed ID: 20015040)
1. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
Ge R; Huang Y; Liang G; Li X
Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040
[TBL] [Abstract][Full Text] [Related]
2. Endogenous inhibitors (GALFs) of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2: derivatives of adrenally produced corticosterone and cortisol.
Morris DJ; Latif SA; Hardy MP; Brem AS
J Steroid Biochem Mol Biol; 2007 May; 104(3-5):161-8. PubMed ID: 17459698
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
Wang M
Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
[TBL] [Abstract][Full Text] [Related]
4. Application of ELISA Technique and Human Microsomes in the Search for 11
Kupczyk D; Studzińska R; Bilski R; Woźniak A
Biomed Res Int; 2019; 2019():5747436. PubMed ID: 31214617
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
Wamil M; Seckl JR
Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
[TBL] [Abstract][Full Text] [Related]
6. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
7. 11{beta}-Hydroxysteroid dehydrogenase 2 in rat leydig cells: its role in blunting glucocorticoid action at physiological levels of substrate.
Ge RS; Dong Q; Niu EM; Sottas CM; Hardy DO; Catterall JF; Latif SA; Morris DJ; Hardy MP
Endocrinology; 2005 Jun; 146(6):2657-64. PubMed ID: 15761036
[TBL] [Abstract][Full Text] [Related]
8. In vivo activity of 11β-hydroxysteroid dehydrogenase type 1 in man: effects of prednisolone and chenodesoxycholic acid.
Diederich S; Quinkler M; Mai K; Schöneshöfer M; Baehr V; Pfeiffer A; Oelkers W; Eigendorff E
Horm Metab Res; 2011 Jan; 43(1):66-71. PubMed ID: 20925019
[TBL] [Abstract][Full Text] [Related]
9. Expression of 11β-hydroxysteroid dehydrogenase 1 and 2 in patients with chronic rhinosinusitis and their possible contribution to local glucocorticoid activation in sinus mucosa.
Jun YJ; Park SJ; Kim TH; Lee SH; Lee KJ; Hwang SM; Lee SH
J Allergy Clin Immunol; 2014 Oct; 134(4):926-934.e6. PubMed ID: 24810847
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the discovery of 11beta-HSD1 inhibitors.
Boyle CD
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):495-511. PubMed ID: 18600567
[TBL] [Abstract][Full Text] [Related]
11. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
Morgan SA; Tomlinson JW
Expert Opin Investig Drugs; 2010 Sep; 19(9):1067-76. PubMed ID: 20707593
[TBL] [Abstract][Full Text] [Related]
12. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
Walker BR
Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
[TBL] [Abstract][Full Text] [Related]
13. Altered activity of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in skeletal muscle confers metabolic protection in subjects with type 2 diabetes.
Jang C; Obeyesekere VR; Dilley RJ; Krozowski Z; Inder WJ; Alford FP
J Clin Endocrinol Metab; 2007 Aug; 92(8):3314-20. PubMed ID: 17519316
[TBL] [Abstract][Full Text] [Related]
14. 11β-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus.
Hollis G; Huber R
Diabetes Obes Metab; 2011 Jan; 13(1):1-6. PubMed ID: 21114597
[TBL] [Abstract][Full Text] [Related]
15. The role of 11beta-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11beta-hsd1 inhibitors.
Saiah E
Curr Med Chem; 2008; 15(7):642-9. PubMed ID: 18336279
[TBL] [Abstract][Full Text] [Related]
16. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity.
Hughes KA; Webster SP; Walker BR
Expert Opin Investig Drugs; 2008 Apr; 17(4):481-96. PubMed ID: 18363514
[TBL] [Abstract][Full Text] [Related]
17. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Masuzaki H; Flier JS
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel 11β-HSD1 inhibitors by combined ligand- and structure-based virtual screening.
Lagos CF; Vecchiola A; Allende F; Fuentes CA; Tichauer JE; Valdivia C; Solari S; Campino C; Tapia-Castillo A; Baudrand R; Villarroel P; Cifuentes M; Owen GI; Carvajal CA; Fardella CE
Mol Cell Endocrinol; 2014 Mar; 384(1-2):71-82. PubMed ID: 24447464
[TBL] [Abstract][Full Text] [Related]
19. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes.
Hamilton BS; Himmelsbach F; Nar H; Schuler-Metz A; Krosky P; Guo J; Guo R; Meng S; Zhao Y; Lala DS; Zhuang L; Claremon DA; McGeehan GM
Eur J Pharmacol; 2015 Jan; 746():50-5. PubMed ID: 25445047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
